Russian scientists inject themselves with the emerging coronavirus, which causes Covid-19, and monkeys steal blood samples of patients who have been infected with the virus in India, and a Chinese vaccine may be ready soon.

These and other developments are reviewed in this report, which follows the latest research developments on the new Corona Virus "SARS Cove 2", which has a number of people infected until today about 6 million, and his death toll has exceeded 368 thousand, according to the Wordlisters website.

And we start from Russia, where scientists at a research institute in Moscow are injecting themselves with a prototype vaccine for the emerging coronavirus, following an unusual but ambitious approach to advancing the global race to find a cure against the pandemic.

The director of the Gamalia Research Institute Alexander Gwensburg did not hesitate to disclose that he had injected himself with a vaccine carried by a non-infectious virus. The use of such a method - contrary to the usual protocols - only implies a desire to accelerate the scientific process as much as possible, in order to complete clinical trials in humans in the summer.

The Gamalia Institute program is one of several projects presented to President Vladimir Putin. Other programs are implemented within public-private partnerships or supervised by the Ministry of Defense.

Many officials went so far as to assure Putin that a vaccine could be produced before the end of the summer, bypassing their promises of dozens of projects under way in China, the United States and Europe.

However, some voices express their fear of confusing speed and haste.

Denounce

In this context, the National Association of Clinical Research Institutions condemned the experiments of Gamalia Institute as "a flagrant violation of the foundations of clinical research, Russian law and international standards".

"I am concerned about promises to produce a vaccine by September ... It reminds me of the race, and I do not like it," said Vitaly Zverev, an official at the General Mechanikov Institute for Vaccines and Sera.

50 projects

The Russian Health Minister, Mikhail Murashko, was quoted by TASS news agency as saying that Russian scientists intend to start clinical trials within two weeks of a vaccine to prevent the emerging corona virus.

"The tests are ongoing, and we intend to start clinical trials in the next two weeks," Murashko said, adding that volunteers were chosen to participate in the experiments.

Kremlin officials said that researchers are working on 50 different projects to develop a vaccine, and there are currently about ten vaccines in the human testing phase, and experts expected that it would take between 12 and 18 months to produce a safe vaccine.

A Russian-administered Victorian institute in Siberia is developing a Russian vaccine, and its director-general said he hoped to complete clinical trials by mid-September, noting that animal experiments had been successful.

Monkeys attack

In India, the authorities said - on Friday - that a group of monkeys attacked a health worker and stole blood samples from patients who were found to be infected with the Coronavirus.

The attack occurred this week when a technician at a laboratory was walking on the campus of a government medical college in Meerut, 460 km north of Lucknow, the capital of Uttar Pradesh state.

Dr. SK Garg, the official at the college, explained that the sample boxes were recovered at a later time without any damage, and said, "The samples are still the same and we do not think that there is any risk of contamination or spread of infection." He added that the three people whose samples were stolen had been tested for the virus again.

Wuhan Institute

On the other hand, the State-owned Assets Supervision and Administration Committee of China stated that a Chinese vaccine to prevent the emerging corona virus may be ready to be put on the market soon, and possibly at the end of this year.

More than 2,000 people taking part in the experiments received vaccines developed by the Wuhan Institute and the Beijing Institute of Biological Products. These vaccines have entered the second stage of clinical trials, knowing that the two institutes belong to the government-appointed Sinopharm Group of Medicines, which is managed by the Asset Control and Management Committee.

According to the commission, the production capacity of the Beijing Institute of Biological Products will be between 100 and 120 million doses annually, and China has five vaccines to prevent the emerging coronavirus in human trials.

initiative

On the other hand, the World Health Organization revealed on Friday an initiative to exchange patents for planned vaccines for Covid-19 disease, but global drug manufacturing departments have made clear they are not interested in such a program.

"The science provides us with solutions, but for these solutions to be feasible for all, we need solidarity," said WHO Director-General Tidros Adhanoum Gherbricos from Geneva at the electronic launch event of the patent pool. He stressed that participation in the patent pool would be voluntary.

The World Health Organization's proposed anti-Covid-19 anti-block pool has won support from 36 countries including Brazil, South Africa, Pakistan, Malaysia, Indonesia, Belgium, the Netherlands and Norway.

For his part, the International Federation of Medicines Associations and Producers "IFMPI" - based in Geneva - in a statement not agreeing with some of the assumptions contained in the plan of the World Health Organization, "as it implies that intellectual property rights have not been diluted or licensed globally, They are potential obstacles. "

Pharmaceutical leaders also warned against collecting patents, but they agreed with the World Health Organization that the planned vaccines for Covid-19 should be made available at reasonable prices to protect citizens in poor and rich countries.

Approval of the remdisiver

In Taiwan, the government said today, Saturday, that it has agreed to use the Gilad Sciences-Synthetic Remedivir drug as a potential treatment for Covid-19 infection, which is caused by infection with the Coronavirus.

The main epidemiological center in Taiwan said that the Taiwan Food and Drug Administration had taken into account “the fact that the efficacy and safety of REMDESIVER is backed by preliminary evidence,” and that other countries have agreed to use it.

On this basis, the center said that the conditions have been met to agree to use the drug to treat "severe" infections with Covid-19.